Litigation Details for Bayer Intellectual Property GMBH v. InvaGen Pharmaceuticals, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Bayer Intellectual Property GMBH v. InvaGen Pharmaceuticals, Inc. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-06-23 |
| Court | District Court, D. Delaware | Date Terminated | 2020-12-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,157,456; 9,539,218 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bayer Intellectual Property GMBH v. InvaGen Pharmaceuticals, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Bayer Intellectual Property GMBH v. InvaGen Pharmaceuticals, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-12-29 | 30 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218. (Attachments: # 1 … 22 December 2020 1:17-cv-00812 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2017-08-01 | 8 | obviousness-type double patenting over claims 13, 24 and 30 of U.S. Patent No. 7,157,456 (“the ’456 patent”) and over… infringement of U.S. Patent No. 9,539,218 (“the ’218 patent”) under the Patent Laws of the United States…claims in a later patent that are not patentably distinct from claims in an earlier patent. See, Eli Lilly…double patenting rejection of claims 1, 4, 5, 11 and 18 of the ’218 patent over the ’456 patent in view…Complaint purports to assert claims of patent infringement under the Patent Laws of the United | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
